🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06603324
Recruiting Not applicable

Analysis of Paediatric Treatments With multiFiltratePRO

NCT06603324 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2025-10-20
Last updated
2026-09-04

Condition(s) studied

Renal FailureCVVHD

Investigational drug(s) / intervention(s)

CVVHD treatment in paediatric mode with multiFiltratePRO

CVVHD treatment in paediatric mode with multiFiltratePRO: Treatment of acute kidney injury paediatric patients with continuous veno-venous haemodiafiltration (CVVHD) in paediatric mode with multiFiltratePRO

Study summary

This clinical study evaluates the performance of the MultifiltratePro in pediatric mode for Continuous Venovenous Hemodiafiltration (CVVHD) in children. Its primary aim is to assess the efficacy of the MultifiltratePro in paediatric mode, specifically in achieving at least 80% of the prescribed effluent dose within 72 hours. Additionally, the study focuses on the safety of this mode in a paediatric setting, closely monitoring for clinical adverse events, hemodynamic instability, and electrolyte imbalances. Paediatric patients with body weights between 8kg and 40kg will be treated with the MultifiltratePro for a period of up to 10 days, with the treatment duration and approach being tailored to the severity of each patient's condition.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion criteria: General: * Paediatric Patients: * Informed consent signed and dated by legal representative and investigator/ authorized physician. * The minors have received the information referred to in Article 63(2) MDR in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children. * The explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in Article 63(2) MDR to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator. Study-specific: * Estimated life expectancy greater than 3 days * Children under 18 years * Body weight ≥8kg and \<40kg * Patients with clinical indication for CVVHD Exclusion criteria: General: * Any conditions which could interfere with the patient's ability to comply with the study * Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations * In case of female patients: pregnancy or lactation period * Participation in an interventional clinical study during the preceding 30 days * Previous participation in the same study Study-specific: * Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT Type II) * Uncontrolled bleeding and coagulation disorders * Decision to limit therapeutic interventions * Inability to establish the required vascular access

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Fakultní nemocnice Ostrava Ostrava-Poruba Czechia Recruiting
Universitätsklinikum Frankfurt Frankfurt Germany Recruiting

More Fresenius Medical Care Deutschland GmbH trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06603324 on ClinicalTrials.gov ↗ ← All trials in Germany